SynthesisScientific reports2025
Effects of the δ-aminolevulinic acid dehydratase polymorphism rs1800435 on blood lead levels: a new systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to lead has various health effects. Studies have correlated the δ-aminolevulinic acid dehydratase (ALAD) polymorphism rs1800435 (ALAD1 and ALAD2) with blood lead levels, but the results have been inconsistent. This meta-analysis evaluated the associations between the rs1800435 and blood lead levels. Studies reporting the relationships of rs1800435 with blood lead levels were included. The sample size, means, and standard deviations were calculated. Subgroup analysis was performed on the basis of the presence or absence of lead exposure, age, sex, and geographic latitude of the investigated people. Twenty-seven studies with 17,344 individuals were included. There was no significant association between rs1800435 status and blood lead levels, either in the lead-exposed group (p = 0.280), nonlead-exposed group (p = 0.642), or overall analysis (p = 0.165). Among those exposed to lead, for people living at non-low latitudes (latitude > 30°), ALAD2 allele carriers had higher lead levels than ALAD1 homozygotes did (p = 0.001). For non-lead-exposed respondents, blood lead levels in male ALAD2 allele carriers demonstrated a marginally significant decrease compared with those in male ALAD1 homozygotes (p = 0.061). Lead exposure levels and the geographical latitude of long-term residence may modify the ALAD2-associated effects on blood lead concentrations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.